| Keyword | CPC | PCC | Volume | Score | Length of keyword |
|---|---|---|---|---|---|
| olaparib breast cancer nejm | 1.85 | 0.9 | 1216 | 69 | 27 |
| olaparib | 0.93 | 1 | 9410 | 81 | 8 |
| breast | 1.45 | 0.1 | 6780 | 39 | 6 |
| cancer | 0.97 | 0.9 | 8941 | 71 | 6 |
| nejm | 0.24 | 0.4 | 9072 | 3 | 4 |
| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| olaparib breast cancer nejm | 1.02 | 0.3 | 1620 | 94 |
| olaparib metastatic breast cancer nejm | 0.37 | 0.4 | 1497 | 46 |
| olaparib and breast cancer | 0.78 | 0.3 | 6417 | 98 |
| olaparib metastatic breast cancer | 1.22 | 0.3 | 7434 | 73 |
| olaparib adjuvant breast cancer | 0.82 | 0.2 | 5837 | 30 |
| olaparib breast cancer approval | 0.92 | 0.4 | 9961 | 26 |
| olaparib breast cancer adjuvant nice | 1.02 | 0.2 | 8288 | 80 |
| olaparib breast cancer uk | 1.29 | 0.7 | 7761 | 33 |
| adjuvant olaparib breast cancer fda | 0.18 | 0.9 | 8656 | 36 |
| olaparib triple negative breast cancer | 1.96 | 0.7 | 1341 | 90 |
| olaparib breast cancer nice | 1.12 | 0.6 | 5495 | 71 |
| olaparib breast cancer indication | 0.52 | 0.7 | 6406 | 65 |
| triple negative breast cancer + olaparib | 0.71 | 0.5 | 3969 | 21 |
| olaparib dose for breast cancer | 1.91 | 0.2 | 5301 | 98 |
| olaparib bevacizumab ovarian cancer nice | 0.39 | 0.5 | 6007 | 4 |
| cancer research uk olaparib | 1.06 | 0.6 | 3138 | 2 |
| olaparib in ovarian cancer | 1.24 | 1 | 5745 | 15 |
| olaparib bevacizumab ovarian cancer | 0.82 | 0.3 | 2770 | 15 |
